Page 293 - Haematologica May 2020

Modeling of FVIII activity, bleeds and covariates
32. Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein- free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360-369.
33. Ljung R, Kenet G, Mancuso ME, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treat- ed children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 2016;22(3):354-360.
34. Shah A, Solms A, Garmann D, et al. Improved Pharmacokinetics with BAY 81- 8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. Clin Pharmacokinet. 2016;56(9):1045- 1055.
35. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (eds). NONMEM 7.4 Users Guides. ICON plc, Gaithersburg, MD. (1989–2018). [https://nonmem.iconplc.com/nonmem743]
36. Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA. Population phar- macokinetic characterization of BAY 81- 8973, a full-length recombinant factor VIII: lessons learned - importance of including
samples with factor VIII levels below the quantitation limit. Haemophilia. 2017;23(4):528-537.
37. Agresti A. Modelling ordered categorical data: recent advances and future challenges. Stat Med. 1999;18(17-18):2191-2207.
38. Sheiner LB. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther. 1994;56(3):309-322.
39. Yngman G, Nyberg J, Jonsson N, Karlsson MO. Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling. 2017. PAGE 26. Abstr 7365 [www.page-meet- ing.org/?abstract=7365].
40. Karlsson MO. A full model approach based on the covariance matrix of parameters and covariates. 2012. PAGE 21. Abstr 2455 [www.page-meeting.org/?abstract=2455].
41. Weiss HJ, Sussman, II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on post- transfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404.
42. Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M. Population pharmaco- kinetics of recombinant factor VIII Fc
fusion protein. Clin Pharmacol Drug Dev.
2015;4(3):163-174.
43. Zhang Y, Roberts J, Tortorici M, et al.
Population pharmacokinetics of recombi- nant coagulation factor VIII-SingleChain in patients with severe hemophilia A. J Thromb Haemost. 2017;15(6):1106-1114.
44. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70 (3):380-385.
45. Carcao MD, van den Berg HM, Ljung R, Mancuso ME. Correlation between pheno- type and genotype in a large unselected cohort of children with severe hemophilia A. Blood. 2013;121(19):3946-3952.
46. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophil- ia. JAMA. 2012;308(14):1452-1459.
47. Abrantes JA, Solms A, Garmann D, Nielsen EI, Jönsson S, Karlsson MO. Bayesian fore- casting utilizing bleeding information to support dose Individualization of factor VIII. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):894-903.
haematologica | 2020; 105(5)
1453